Saturday 17 October 2026
Export GRCE’s income statement to Excel — free account
Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
1.89
0.06
−3.08%
Follow GRCE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
13.56 | 14.56 | 7.92 | 11.02 | |
Current Ratio |
13.89 | 14.96 | 8.10 | 11.47 | |
Net Debt/EBITDA |
6.67 | 7.63 | 5.65 | 0.86 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.35 | 0.96 | 1.44 | 0.20 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.74 | 0.72 | 0.74 | 0.71 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.13) | (0.10) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.13) | (0.10) | (0.19) | |
Cash per Share |
1.06 | 1.10 | 1.03 | 0.80 | |
Shareholders Equity per Share |
3.94 | 3.83 | 3.87 | 2.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.94 | 3.83 | 3.87 | 2.79 | |
Free Cash Flow |
(3.14) | (2.23) | (1.69) | (3.22) | |
Working Capital |
16.05 | 17.93 | 15.23 | 13.08 | |
Net Current Asset Value |
13.54 | 15.62 | 14.62 | 12.47 | |
| Other line items | |||||
Average Receivables |
0.22 | 0.16 | 0.07 | 0.02 | |
Average Payables |
1.96 | 1.63 | 2.04 | 1.78 | |
Average Assets |
65.96 | 64.86 | 69.32 | 59.94 | |
Average Common Equity |
59.48 | 58.52 | 65.25 | 55.88 |
Columns are period end dates